Sunstone: IPO kickstarted Santaris sale
Plans for a US IPO were what eventually led to the sale of Santaris to a Big Pharma outfit that Martin Bonde calls “the biggest gorilla in the jungle” – and it is a sale that could have a huge significance for other Danish biotechs.
BY STEFAN SINGH KAILAY
An IPO can sometimes make a partnership between a biotech company and its Big Pharma partner more difficult. According to Claus Andersson, partner in Sunstone Capital and Vice Chairman in Santaris Pharma, that might be what led Swiss drug giant Roche to buy Santaris for USD 250 million and potentially USD 200 million extra in milestone payments.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
“I think they have done a great job”
For abonnenter
